Sprim Als Blog Cilcare completes a 40M series A

The funds will support two Phase 2a clinical trials for the drug candidate CIL001, targeting cochlear synaptopathy (a leading cause of difficulty understanding speech in noise, tinnitus, and hyperacusis), as well as the advancement of preclinical development for the candidate ... Read More The post Cilcare completes a €40M series A appeared first on SPRIM.